Name | Number of supported studies | Average coverage | |
---|---|---|---|
plasma cell | 14 studies | 33% ± 15% | |
IgG plasma cell | 10 studies | 63% ± 24% | |
B cell | 6 studies | 23% ± 5% | |
plasmablast | 4 studies | 37% ± 21% |
Insufficient scRNA-seq data for expression of IGHG4 at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
lung | 85% | 1731.29 | 491 / 578 | 77% | 607.33 | 888 / 1155 |
stomach | 62% | 549.77 | 222 / 359 | 61% | 279.48 | 174 / 286 |
thymus | 76% | 4394.95 | 496 / 653 | 37% | 425.91 | 224 / 605 |
liver | 93% | 915.34 | 210 / 226 | 17% | 46.98 | 69 / 406 |
intestine | 52% | 2127.01 | 500 / 966 | 56% | 278.86 | 296 / 527 |
spleen | 100% | 27905.89 | 240 / 241 | 0% | 0 | 0 / 0 |
esophagus | 33% | 1388.99 | 476 / 1445 | 58% | 345.26 | 107 / 183 |
breast | 31% | 232.08 | 142 / 459 | 54% | 195.70 | 608 / 1118 |
bladder | 33% | 652.62 | 7 / 21 | 52% | 297.41 | 260 / 504 |
uterus | 35% | 319.54 | 60 / 170 | 43% | 173.46 | 198 / 459 |
tonsil | 0% | 0 | 0 / 0 | 78% | 721.13 | 35 / 45 |
lymph node | 0% | 0 | 0 / 0 | 62% | 246.66 | 18 / 29 |
kidney | 46% | 2260.92 | 41 / 89 | 15% | 56.00 | 134 / 901 |
pancreas | 4% | 148.83 | 14 / 328 | 55% | 389.39 | 98 / 178 |
prostate | 45% | 1267.02 | 110 / 245 | 12% | 37.23 | 59 / 502 |
peripheral blood | 57% | 776.82 | 525 / 929 | 0% | 0 | 0 / 0 |
skin | 6% | 79.39 | 115 / 1809 | 48% | 293.47 | 226 / 472 |
adipose | 45% | 1509.49 | 542 / 1204 | 0% | 0 | 0 / 0 |
ovary | 26% | 144.16 | 47 / 180 | 16% | 30.76 | 68 / 430 |
adrenal gland | 18% | 76.39 | 47 / 258 | 4% | 8.88 | 10 / 230 |
blood vessel | 21% | 592.53 | 281 / 1335 | 0% | 0 | 0 / 0 |
heart | 8% | 95.85 | 72 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 4% | 7.61 | 3 / 80 |
brain | 1% | 4.39 | 33 / 2642 | 1% | 3.08 | 10 / 705 |
muscle | 1% | 7.66 | 10 / 803 | 0% | 0 | 0 / 0 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0002250 | Biological process | adaptive immune response |
GO_0050853 | Biological process | B cell receptor signaling pathway |
GO_0006958 | Biological process | complement activation, classical pathway |
GO_0019731 | Biological process | antibacterial humoral response |
GO_0005615 | Cellular component | extracellular space |
GO_0042571 | Cellular component | immunoglobulin complex, circulating |
GO_0071735 | Cellular component | IgG immunoglobulin complex |
GO_0072562 | Cellular component | blood microparticle |
GO_0070062 | Cellular component | extracellular exosome |
GO_0005576 | Cellular component | extracellular region |
GO_0005886 | Cellular component | plasma membrane |
GO_0034987 | Molecular function | immunoglobulin receptor binding |
GO_0003823 | Molecular function | antigen binding |
Gene name | IGHG4 |
Protein name | Immunoglobulin heavy constant gamma 4 (Ig gamma-4 chain C region) |
Synonyms | |
Description | FUNCTION: Constant region of immunoglobulin heavy chains. Immunoglobulins, also known as antibodies, are membrane-bound or secreted glycoproteins produced by B lymphocytes. In the recognition phase of humoral immunity, the membrane-bound immunoglobulins serve as receptors which, upon binding of a specific antigen, trigger the clonal expansion and differentiation of B lymphocytes into immunoglobulins-secreting plasma cells. Secreted immunoglobulins mediate the effector phase of humoral immunity, which results in the elimination of bound antigens . The antigen binding site is formed by the variable domain of one heavy chain, together with that of its associated light chain. Thus, each immunoglobulin has two antigen binding sites with remarkable affinity for a particular antigen. The variable domains are assembled by a process called V-(D)-J rearrangement and can then be subjected to somatic hypermutations which, after exposure to antigen and selection, allow affinity maturation for a particular antigen . . |
Accessions | ENST00000618981.2 [P01861-1] P01861 ENST00000641978.1 [P01861-2] ENST00000390543.3 [P01861-1] |